Physician_Profile_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Record_ID,Name_of_Associated_Covered_Drug_or_Biological1,Name_of_Associated_Covered_Drug_or_Biological2,Name_of_Study,Research_Information_Link,Context_of_Research
505503,"Valeant Pharmaceuticals North America LLC",NJ,100000010935,1480.00,04/24/2015,"Cash or cash equivalent",294360452,PROVENGE,"","A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER","",""
505503,"Valeant Pharmaceuticals North America LLC",NJ,100000010935,1295.00,08/13/2015,"Cash or cash equivalent",294360458,PROVENGE,"","A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER","",""
505503,"Valeant Pharmaceuticals North America LLC",NJ,100000010935,1295.00,12/10/2015,"Cash or cash equivalent",294360462,PROVENGE,"","A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER","",""
